Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

Now Viewing

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

In this episode, experts discuss how bispecific antibodies are reshaping the treatment landscape for relapsed or refractory multiple myeloma. Panelists explain that the introduction of this drug class has expanded therapeutic expectations, allowing more patients to achieve deep and durable responses, even in later treatment stages. They highlight the four currently available bispecific T cell engagers, noting their differing targets and routes of administration. The conversation then shifts to how clinicians define lines of therapy in practice. Experts outline the formal criteria while acknowledging the complexity that arises when patients require regimen adjustments for intolerance or clinical urgency. They emphasize that future trial design may move toward categorizing patients by prior drug class exposure rather than rigid line counts. Panelists note that real world practice sometimes involves creative sequencing to ensure timely access to bispecifics, underscoring ongoing debates around how treatment lin